These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 8095240)

  • 21. Functional and binding characteristics of long-acting beta 2-agonists in lung and heart.
    Roux FJ; Grandordy B; Douglas JS
    Am J Respir Crit Care Med; 1996 May; 153(5):1489-95. PubMed ID: 8630591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacologic characterization of formoterol in comparison with isoprenaline, fenoterol and salbutamol in tracheal muscle strips and lung membranes of the guinea pig].
    Lemoine H; Worth H; Reinhardt D
    Pneumologie; 1993 Apr; 47(4):303-10. PubMed ID: 8506253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nebulized fenoterol causes greater cardiovascular and hypokalaemic effects than equivalent bronchodilator doses of salbutamol in asthmatics.
    Bremner P; Burgess C; Beasley R; Woodman K; Marshall S; Crane J; Pearce N
    Respir Med; 1992 Sep; 86(5):419-23. PubMed ID: 1462021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The extrapulmonary effects of inhaled hexoprenaline and salbutamol in healthy individuals.
    Bremner P; Burgess C; Purdie G; Beasley R; Crane J
    Eur J Clin Pharmacol; 1993; 45(1):37-9. PubMed ID: 8405027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The extrapulmonary effects of increasing doses of formoterol in patients with asthma.
    Burgess C; Ayson M; Rajasingham S; Crane J; Della Cioppa G; Till MD
    Eur J Clin Pharmacol; 1998 Apr; 54(2):141-7. PubMed ID: 9626918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol.
    Grove A; Lipworth BJ
    Thorax; 1996 Jan; 51(1):54-8. PubMed ID: 8658370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effect of a single dose of formoterol using an aerosol inhaler in asthmatic children. A randomized, controlled, double-blind study].
    Lebecque P; Vliers S; De Saint-Moulin T; Godding V
    Rev Mal Respir; 1994; 11(1):47-50. PubMed ID: 7907426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of the extent and duration of hypokalaemia following three nebulized beta 2-adrenoceptor agonists.
    Burgess CD; Flatt A; Siebers R; Crane J; Beasley R; Purdie G
    Eur J Clin Pharmacol; 1989; 36(4):415-7. PubMed ID: 2567672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients.
    Lipworth BJ; Newnham DM; Clark RA; Dhillon DP; Winter JH; McDevitt DG
    Thorax; 1995 Jan; 50(1):54-61. PubMed ID: 7886650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The duration of action of inhaled formoterol dry powder.
    Quebe-Fehling E; Brambilla R; Bromly CL; Fishwick K; Walters EH; Hendrick DJ
    Br J Clin Pract; 1996 Dec; 50(8):446-9. PubMed ID: 9039716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of inhaled formoterol compared with salbutamol in ventilated preterm infants.
    Rieger-Fackeldey E; Reinhardt D; Schulze A
    Pulm Pharmacol Ther; 2004; 17(5):293-300. PubMed ID: 15477125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
    Aziz I; Hall IP; McFarlane LC; Lipworth BJ
    J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cardiovascular effects of beta adrenergic agonist drugs administered by nebulisation.
    Flatt A; Crane J; Purdie G; Kwong T; Beasley R; Burgess C
    Postgrad Med J; 1990 Feb; 66(772):98-101. PubMed ID: 2349198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
    Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
    Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a long- and short-acting beta2-agonist on exercise-induced arterial hypoxemia.
    Stewart IB; Labreche JM; McKenzie DC
    Med Sci Sports Exerc; 2003 Apr; 35(4):603-7. PubMed ID: 12673143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protective effect and duration of action of formoterol aerosol on exercise-induced asthma.
    Patessio A; Podda A; Carone M; Trombetta N; Donner CF
    Eur Respir J; 1991 Mar; 4(3):296-300. PubMed ID: 1677894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers.
    Scheinin M; Koulu M; Laurikainen E; Allonen H
    Br J Clin Pharmacol; 1987 Nov; 24(5):645-53. PubMed ID: 2829953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiopulmonary effects of fenoterol and salbutamol aerosols.
    Tandon MK
    Chest; 1980 Mar; 77(3):429-31. PubMed ID: 7357948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of inhaled powders of fenoterol and salbutamol in asthma.
    Asher MI; Dunn C
    Aust Paediatr J; 1985 May; 21(2):119-21. PubMed ID: 3899082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-effect relationship of the beta-agonists fenoterol and salbutamol in patients with asthma.
    Newhouse MT; Dolovich MB; Kazim F
    Chest; 1994 Jun; 105(6):1738-42. PubMed ID: 8205869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.